Updated:
PathAI
At PathAI, we’re dedicated to improving patient outcomes with AI-powered pathology and meaningful collaboration with biopharma, laboratories and clinicians.
PathAI
At PathAI, we’re dedicated to improving patient outcomes with AI-powered pathology and meaningful collaboration with biopharma, laboratories and clinicians.
General information
Firm type
Asset Manager
Location
Region
North America
Country
United States
City
Boston
Corporate office
Boston, MA, United States
Additional offices
Princeton, NJ, United States · Burlington, MA, United States
Sector focus
Frequently asked questions
How does PathAI generate proprietary deal flow or revenue?
PathAI generates revenue through biopharma collaborations for biomarker discovery and drug development, deployment of its AISight platform to anatomic pathology laboratories, and its pathologist contributor network that provides annotation services for AI training (per the firm). The firm does not disclose revenue figures.
Does PathAI participate in fund commitments or only direct deals?
PathAI operates as a venture-backed company, not as an asset manager making fund commitments. Its capital is deployed into product development, clinical trials, and commercial partnerships.
What investment stages does PathAI typically target?
PathAI does not invest externally. It raises venture capital for its own operations; no public information on stage focus is available.
Which sectors does PathAI explicitly focus on?
PathAI focuses exclusively on pathology and artificial intelligence for healthcare. Its products serve biopharma and clinical laboratories.
How is PathAI related to any spinout or parent entity?
PathAI Diagnostics, the entity providing anatomic and digital pathology laboratory services, had select assets acquired by AmeriPath (a Quest Diagnostics company) on June 10, 2024 (per the firm). PathAI continues to operate its core technology and biopharma business.
Does PathAI maintain philanthropic structures?
No public information on philanthropic structures is available.
What is PathAI's known posture on co-investments alongside external GPs?
PathAI does not make co-investments alongside external GPs; it is an operating company not structured as an investment vehicle.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on asset managers?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: